Highlights in Ovarian Cancer

Publisher Website
Google Scholar
Abstract
The ovarian cancer presentations at the 2000 ASCO meeting did not yield any major paradigm shifts in the treatment of women with epithelial ovarian cancer. Emphasis at this year's meeting focused on the potential incorporation of drugs such as topotecan, oxaliplatin, doxil, and gemcitabine into the initial treatment strategies of women with advanced ovarian cancer. These studies included the introduction of several active and tolerable regimens that are potentially worthy of direct comparison to the carboplatin and paclitaxel combination. In the woman with recurrent or persistent ovarian cancer there was a greater focus on phase III studies directly comparing various chemotherapy strategies in the treatment of women with recurrent disease. This included the comparisons of single-versus two-drug salvage regimens, alternate salvage schedules, and direct comparison of agents active in taxane- and platinum-resistant disease. Finally, several early studies of novel non-chemotherapeutic strategies were presented.